Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: Impact on the activity of imipenem, meropenem and doripenem

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 9, 2011, Pages 2022-2027

  Riera, Elena ^a   Cabot, Gabriel ^a   Mulet, Xavier ^a   García Castillo, María ^b   del Campo, Rosa ^b   Juan, Carlos ^a   Cantón, Rafael ^b   Oliver, Antonio ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

AmpC; Antibiotic resistance mechanisms; Carbapenemases; Efflux pumps; OprD; P. aeruginosa

Indexed keywords

BETA LACTAMASE AMPC; CARBAPENEM; DORIPENEM; IMIPENEM; MEMBRANE PROTEIN; MEROPENEM; METALLO BETA LACTAMASE; PROTEIN MEXB; PROTEIN MEXD; PROTEIN MEXF; PROTEIN MEXY; PROTEIN OPRD; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; BACTERIUM ISOLATE; DRUG ACTIVITY; ENZYME INACTIVATION; ENZYME SYNTHESIS; GENE EXPRESSION; GENE SEQUENCE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPAIN;

EID: 79960943589     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr232     Document Type: Article

References (29)

1. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009; 22: 582-610.
2. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34: 634-40.
3. Moya B, Zamorano L, Juan C et al. Activity of a new cephalosporin, CXA-101 (FR264205), against ß-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother 2010; 54: 1213-7.
4. Livermore DM, Mushtaq S, Warner M. Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gramnegative bacteria with characterized resistance mechanisms. J Antimicrob Chemother 2010; 65: 2382-95.
5. Mushtaq S, Warner M, Livermore DM. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother 2010; 65: 2376-81.
6. Pillar CM, Torres MK, Brown NP et al. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother 2008; 52: 4388-99.
7. Davies TA, Shang W, Bush K et al. Affinity of doripenem and comparators to penicillin-binding proteins of Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008; 52: 1510-2.
8. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004; 48: 3086-92.
9. Hocquet D, Berthelot P, Roussel-Delvallez M et al. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob Agents Chemother 2007; 51: 3531-6.
10. Gutiérrez O, Juan C, Cercenado E et al. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. Antimicrob Agents Chemother 2007; 51: 4329-35.
11. Moya B, Döstch A, Juan C et al. ß-Lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PLoS Pathog 2009; 5: e1000353.
12. Rodríguez-Martínez JM, Poirel L, Nordmann P. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53: 4783-8.
13. Gimeno C, Cantón R, García A et al. Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study. Rev Esp Quimioter 2010; 23: 144-52.
14. Nordmann P, Picazo JJ, Mutters R et al. Comparative activity of carbapenem testing: the COMPACT study. J Antimicrob Chemother 2011; 66: 1070-8.
15. Oh H, Stenhoff S, Jalal S et al. Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains. Microb Drug Res 2003; 8: 323-8.
16. Juan C, Moyá B, Pérez JL et al. Stepwise upregulation of the Pseudomonas aeruginosa chromosomal cephalosporinase conferring high-level ß-lactam resistance involves three AmpD homologues. Antimicrob Agents Chemother 2006; 50: 1780-7.
17. Cabot G, Ocampo-Sosa AA, Tubau F et al. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob Agents Chemother 2011; 55: 1906-11.
18. Quénée L, Lamotte D, Polack B. Combined sacB-based negative selection and cre-lox antibiotic marker recycling for efficient gene deletion in Pseudomonas aeruginosa. Biotechniques 2005; 38: 63-7.
19. Filip C, Fletcher G, Wulf JL et al. Solubilization of the cytoplasmic membrane of Escherichia coli by the ionic detergent sodium-lauryl sarcosinate. J Bacteriol 1973; 115: 717-22.
20. Fritsche TR, Sader HS, Toleman MA et al. Emerging metallo-b-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program. Clin Infect Dis 2005; 41: S276-8.
21. Lee K, Lee WG, Uh Y et al. VIM- and IMP-type metallo-b-lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals. Emerg Infect Dis 2003; 9: 868-71.
22. Rossolini GM, Luzzaro F, Migliavacca R et al. First countrywide survey of acquired metallo-b-lactamases in gram-negative pathogens in Italy. Antimicrob Agents Chemother 2008; 52: 4023-9.
23. Mulet X, Ocete MD, Juan C et al. Nosocomial spread of a multidrug-resistant Pseudomonas aeruginosa strain, producing the novel metallo-b-lactamase variant VIM-20, in a Spanish hospital. Clin Microbiol Infect 2010; 16 Suppl 2: S197 (P774).
24. Crandon JL, Bulik CC, Nicolau DP. In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53: 4352-6.
25. Louie A, Bied A, Fregeau C et al. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. Antimicrob Agents Chemother 2010; 54: 2638-45.
26. Samtani MN, Flamm R, Kaniga K et al. Pharmacokineticpharmacodynamic-model-guided doripenem dosing in critically ill patients. Antimicrob Agents Chemother 2010; 54: 2360-4.
27. Quale J, Bratu S, Gupta J et al. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2006; 50: 1633-41.
28. Rodríguez-Martínez JM, Poirel L, Nordmann P. Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53: 1766-71.
29. Zamorano L, Moyá B, Juan C et al. Differential ß-lactam resistance response driven by ampD or dacB (PBP4) inactivation in genetically diverse Pseudomonas aeruginosa strains. J Antimicrob Chemother 2010; 65: 1540-2.